

Claris sets up new anti-infective injectable unit

Times of India, Ahmedabad, November 20, 2009
Undertakes Further Expansion Of Rs 90 Crore



Ahmedabad: Claris Lifesciences Ltd, the Ahmedabad based pharma major specialising in manufacturing sterile injectables, has set up a new manufacturing facility for anti-infective injectable at the company's existing state-of-the-art manufacturing plant at Changodar, near Ahmedabad.

The new facility, an extension of its existing USFDA approved injectables plant, has been set up at an investment of Rs 75 crore and has a capacity of 5 million units. With the new facility's commissioning, the company's total manufacturing capacity has gone up to 15 million units. Besides, anti-infective injectable, the new unit will also produce injectable for clinical nutrition segment. As the new facility is designed keeping in mind the highest standards of technology and quality, the company is being geared to get approvals from all leading regulatory agencies like USFDA, MHRA-UK, TGA-Australia and ANVISA-Brazil for the new plant. The company in May 2009 inked the partnership deal with Pfizer to get access to regulated markets like US and Europe by leveraging its manufacturing facilities and products. "With regulated markets growing and the new product pipeline looking good, we believe this facility will be a key growth driver for the company", said Arjun Handa, managing director and chief executive officer. Over the coming years this capacity expansion may result into topline growth of about 20% spread over the next couple of years and a bottomline of about 25%. This is the largest injectable plant in India to house such technologies under one roof, Handa added. will be on high-complex products. For Pfizer, which does not have a presence in generic injectables, it would mean adding one more category to complement its portfolio in the generics space.

Clariss is also undertaking another expansion by infusing Rs 90-crore investment for enhancing production capacities for various therapeutic segments like anaesthesia, clinical nutrition, anti-infectives and generic injectables. The expansion process is expected to be completed in next 18 months, after which, the firm's total capacity would reach 30 million units.

At present, the company has global footprint across 76 countries, operating in the critical care segment, with special focus on high-end injectables, including sterile parenteral preparations, life-saving medicines and other hospital products for treatment of critical illnesses and diseases.